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Abstract 22 
  Dihydroartemisinin-piperaquine (DHA-PQ) is under study for intermittent preventive 23 
treatment during pregnancy (IPTp), but it may accelerate selection for drug resistance. 24 
Understanding the relationships between piperaquine concentration, prevention of parasitemia, 25 
and selection for decreased drug sensitivity can inform control policies and optimization of 26 
DHA-PQ dosing. Piperaquine concentrations, measures of parasitemia, and Plasmodium 27 
falciparum genotypes associated with decreased aminoquinoline sensitivity in Africa (pfmdr1 28 
86Y, pfcrt 76T) were obtained from pregnant Ugandan women randomized to IPTp with 29 
sulfadoxine-pyrimethamine (SP) or DHA-PQ.  Joint pharmacokinetic/pharmacodynamic models 30 
described relationships between piperaquine concentration and probability of genotypes of 31 
interest using nonlinear mixed effects modeling. Increasing piperaquine plasma concentration 32 
was associated with a log-linear decrease in risk of parasitemia. Our models predicted that higher 33 
median piperaquine concentrations would be required to provide 99% protection against mutant 34 
compared to wild type infections (pfmdr1 N86: 9.6 ng/mL, 86Y: 19.6 ng/mL; pfcrt K76: 6.5 35 
ng/mL, 76T: 19.6 ng/mL). Comparing monthly, weekly, and daily dosing, daily low dose DHA-36 
PQ was predicted to result in the fewest infections and the fewest mutant infections per 1,000 37 
pregnancies (predicted mutant infections for pfmdr1 86Y: SP monthly: 607, DHA-PQ monthly: 38 
198, DHA-PQ daily: 1; for pfcrt 76T: SP monthly: 1564, DHA-PQ monthly: 283, DHA-PQ 39 
daily: 1). Our models predict that higher piperaquine concentrations are needed to prevent 40 
infections with pfmdr1/pfcrt mutant compared to wild type parasites and that, despite selection 41 
for mutants by DHA-PQ, the overall burden of mutant infections is lower for IPTp with DHA-42 
PQ than for IPTp with SP. 43 
 44 
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Manuscript 45 
Introduction  46 
 Plasmodium falciparum infection during pregnancy, especially during a first pregnancy, 47 
places infants at risk for the complications of placental malaria, including intrauterine growth 48 
retardation, preterm birth, low birth weight, and death (1). The World Health Organization 49 
recommends that pregnant women at risk for malaria in Africa use a long lasting insecticide 50 
treated bed net and receive at least three doses of sulfadoxine-pyrimethamine (SP) as intermittent 51 
preventive treatment during pregnancy (IPTp) (2). However, in much of Africa, including east 52 
Africa, the protective efficacy of SP as chemoprevention for pregnant women and children is 53 
inadequate (3-5). Compared to three doses of SP during pregnancy, a monthly course of 54 
dihydroartemisinin-piperaquine (DHA-PQ), an artemisinin-based combination therapy 55 
administered once daily for three days, dramatically reduced the prevalence of maternal 56 
parasitemia and placental malaria in Uganda and Kenya (5, 6). 57 
Pharmacokinetic/pharmacodynamic (PK/PD) modeling studies found that plasma piperaquine 58 
(PQ) concentrations are excellent predictors of DHA-PQ protective efficacy, and that 59 
maintaining higher PQ concentrations in the target population, such as with lower dose weekly 60 
or daily DHA-PQ, predicts maximal protective efficacy (7-10).  61 
The long half-life of PQ makes DHA-PQ an ideal choice for malaria chemoprevention, 62 
but antimalarials with the longest half-lives may be at the greatest risk for resistance selection 63 
(11). Although true resistance to DHA-PQ, as observed in southeast Asia (12, 13), has not been 64 
confirmed in Africa (14-16), P. falciparum infections that emerge following DHA-PQ treatment 65 
have had, compared to parasites not under drug selection, increased prevalence of mutant 66 
genotypes in the putative drug transporters pfmdr1 (86Y) and pfcrt (76T) (14, 16, 17). These 67 
mutations are associated with decreased sensitivity to chloroquine and amodiaquine, two 68 
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aminoquinolines related to piperaquine (14), and these results raise the concern that using DHA-69 
PQ for chemoprevention may provide only a short-term benefit, with eventual loss of efficacy 70 
due to accelerated development of resistance. 71 
We are interested in optimizing DHA-PQ dosing during IPTp to maximize protective 72 
efficacy, minimize toxicity, and limit selection for less drug sensitive parasites. In this analysis, 73 
we used clinical, pharmacokinetic, and molecular data from a trial of pregnant women who were 74 
randomized to receive DHA-PQ or SP as IPTp to develop PK/PD models which quantified 75 
relationships between PQ exposure, parasitemia, and genetic markers associated with decreased 76 
drug sensitivity. We then used the concentration-effect relationships to predict how 77 
modifications to DHA-PQ dosing would impact the burden of P. falciparum infection, including 78 
the risk of infection with parasites with decreased drug sensitivity. 79 
Results 80 
Study cohort and data collection 81 
 Data were from a randomized controlled trial, in which 300 pregnant women were 82 
randomized to one of three IPTp regimens: SP every 8 weeks beginning at gestational week 20, 83 
DHA-PQ every 8 weeks beginning gestational week 20, or DHA-PQ every 4 weeks beginning at 84 
gestational weeks 16 or 20 as previously described (Figure 1, Table 1) (5). Clinical 85 
characteristics were similar between the three study arms (Table 1). Participants returned 86 
monthly for routine visits and for any acute illness. At routine visits or when malaria was 87 
suspected, evaluation included a capillary or venous blood draw for plasma PQ concentration 88 
and parasite detection. If the woman was parasitemic, the parasite was genotyped at pfmdr1 86 89 
and pfcrt 76 (16). A subset of 30 women underwent intensive PQ sampling. A total of 652 90 
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venous and 558 capillary PQ concentrations were obtained (Table 1, Supplemental Figure 1). 91 
Genotyping for the single nucleotide polymorphisms at pfmdr1 N86Y and pfcrt K76T was 92 
successful for >84% of episodes of parasitemia in the SP arm, and >93% in the DHA-PQ arms. 93 
Prevalences of mutant genotypes were higher in the DHA-PQ arms compared to the SP arm 94 
(pfmdr1 86Y: SP 27%, DHA-PQ 65%; pfcrt 76T: SP 82%, DHA-PQ 87%), as previously 95 
reported (Table 1) (16).  96 
PK/PD model building 97 
 Simultaneous continuous-categorical PK/PD models were developed using a mixed-98 
effects logistic regression approach. Models were evaluated using objective function value 99 
(OFV), with a decrease in OFV (ΔOFV) of -3.84 considered a significant improvement if one 100 
parameter was added to the model, and by visual predictive check (Supplemental Figure 2). Two 101 
types of simultaneous PK/PD models were developed for the analysis. PK/PD-parasitemia 102 
models predicted the risk of parasitemia. PK/PD-resistance models predicted the risk of a mutant 103 
infection at pfmdr1 86 or pfcrt 76 when parasitemia was detected.  104 
A two-compartment model for PQ was used to predicted plasma concentrations, as 105 
previously described (8). For the PK/PD-parasitemia model for women who received DHA-PQ, 106 
a negative log-linear relationship provided an adequate fit for the association between plasma PQ 107 
concentration and risk of parasitemia (ΔOFV -230, Supplemental Figure 2b). Being primigravida 108 
was associated with a significant 26.6% increased risk of parasitemia prior to IPTp compared to 109 
being multigravida participants (ΔOFV -24). However, after initiation of DHA-PQ gravidity was 110 
not a significant predictor of parasitemia in the model. Significant covariates after initiation of 111 
IPTp included being in the second or third trimester, and household receipt of indoor residual 112 
spraying of insecticide (IRS).  Compared to the second trimester, the third trimester was 113 
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associated with a 19.0% reduction in risk of parasitemia while receiving IPTp (ΔOFV -41). 114 
Finally, receipt of IRS, which in the clinical trial only occurred after the start of 115 
chemoprevention, was associated with complete protection from parasitemia, eliminating the 116 
concentration effect of PQ when present (ΔOFV -36) (Table 2). Additional covariates tested 117 
included body mass index (BMI) at enrollment, change in BMI compared to enrollment, and 118 
presence of dry season, and these were not significantly associated with the risk of parasitemia 119 
for women who received DHA-PQ. Gravidity, trimester, and BMI were also tested as covariates 120 
on the relationship between PQ and risk of parasitemia; these did not significantly improve the 121 
PK/PD-parasitemia model for DHA-PQ. The final model for the probability of parasitemia is 122 
described in Equation 1, where P is the probability of parasitemia; B is the baseline risk of 123 
parasitemia; sl is the slope of the concentration dependent change in probability; [PQ] is the PQ 124 
concentration in ng/mL; θ represents covariates that were estimated in the model; and 𝜀 and 𝜂 125 
indicate residual error. 126 
Logit (P) = 𝐵 + 𝑠𝑙*[PQ] +  𝜃IRS + 𝜃Trimester + 𝜀 + 𝜂  (Eq1) 127 
For women who were not exposed to IRS, even low PQ concentrations were associated 128 
with a decreased risk of parasitemia as compared to baseline, and PQ was a predictor of 129 
parasitemia risk regardless of the trimester (Figure 2).  130 
 For SP, pharmacokinetic data were not available, and a PD model for parasitemia was 131 
developed. In a stepwise manner, binary covariates were added to the baseline probability of 132 
parasitemia for the SP PD-parasitemia model as seen in Equation 2, where P is the probability of 133 
parasitemia; B is the baseline risk of parasitemia; θ represents covariates that were estimated in 134 
the model; and 𝜀 and 𝜂 indicate residual error.  135 
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Logit (P) = 𝐵 + 𝜃IRS + 𝜃Season + 𝜀 + 𝜂  (Eq2) 136 
 Similar to DHA-PQ, being primigravid significantly increased the risk of parasitemia prior to 137 
IPTp by 23.3% (ΔOFV -8.0). Receipt of IRS was associated with a reduced risk of parasitemia 138 
(32.7%, Table 2, ΔOFV -27). In addition, for the SP arm the dry season was independently 139 
associated with a decreased risk of parasitemia (24.4%, ΔOFV -17). After adjusting for 140 
significant covariates, the model did not support the addition of an SP effect (added as time 141 
varying, treatment arm effect, or binary covariate). In addition, enrollment BMI, change in BMI 142 
and trimester were not associated with significant changes in risk of parasitemia. 143 
 PK/PD-resistance models were then developed to estimate the probability of a mutant 144 
infection at pfmdr1 N86Y or pfcrt K76T. A log-linear relationship between PQ concentration and 145 
probability of a mutant infection provided the best fit for both pfmdr1 86Y (ΔOFV -11) and pfcrt 146 
76T (ΔOFV -9.6) (Supplemental Figure 2c, 2d). Increasing PQ concentrations were associated 147 
with an increased probability of a mutant infection at both loci (Figure 3). As expected, there was 148 
no significant relationship between IPTp with SP and detection of a mutant pfmdr1 86Y or pfcrt 149 
76T allele. Compared to the SP group, the odds of detecting pfmdr1 86Y increased with 150 
increasing PQ concentration, with a maximum median odds of 4.3 occurring at 17.9 ng/mL PQ 151 
(Figure 3c). In the setting of a high baseline risk of pfcrt 76T, PQ exposure was associated with a 152 
slight increase in the odds of detecting a mutant compared to the SP arm, peaking at a maximum 153 
median odds of 1.3 at 10.1 ng/mL PQ (Figure 3c).  154 
Derivation of PQ concentration targets 155 
 The PQ concentrations required to prevent 99% of parasitemia episodes varied by 156 
trimester. Women in the second trimester were predicted to require 19.6 ng/mL PQ (95% CI 157 
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13.2-31.6) to achieve 99% protection from parasitemia, while in the third trimester 12.8 ng/mL 158 
(9.2-19.2) was required. 159 
The PQ concentrations required to prevent 99% of parasitemia episodes stratified by wild 160 
type and mutant genotypes were derived from a joint model of the final PK/PD models for 161 
predicting parasitemia and genotype. Since women in the second trimester were predicted to 162 
require the highest PQ concentrations for protection (Supplemental Table 1), this population was 163 
used to estimate the target protective concentrations, as shown in Figure 4.  For pfmdr1 86, an 164 
increased risk of mutant parasites was predicted compared to baseline at sub-protective plasma 165 
concentrations of PQ, peaking at 3.3 ng/mL (Figure 2). PQ concentrations required to prevent 166 
99% of parasitemia episodes were predicted to be higher for parasites with mutant pfmdr1 86Y 167 
(19.6 ng/mL, [95% CI 12.9-32.2]) compared to wild type pfmdr1 N86 (9.6 ng/mL [7.0-12.4]) 168 
and for mutant pfcrt 76T (19.6 ng/ml [13.1-32.2]) compared to wild type pfcrt K76 (6.5 ng/ml 169 
[4.1-9.3]) (Figure 4).  170 
Simulations to predict the optimal DHA-PQ dosing schedule  171 
Simulations were conducted of 1,000 women who received SP every 8 weeks or DHA-172 
PQ monthly, weekly, or daily using the joint PK/PD models to estimate the percentage of time 173 
above protective concentrations during pregnancy and the predicted number of mutant pfmdr1 174 
86Y and pfcrt 76T infections for each regimen (Table 3, Figure 5).  All simulations assumed no 175 
exposure to IRS or seasonal variation. Both the number of parasitemia episodes and the number 176 
of mutant parasitemia episodes were predicted to be lower with any of the considered DHA-PQ 177 
regimens compared to SP. Low dose (320 mg PQ per day) daily DHA-PQ was predicted to result 178 
in the lowest median number of infections and mutant infections, with an estimated reduction in 179 
mutant infections >99%.  180 
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Discussion 181 
 A monthly treatment course of DHA-PQ markedly reduced the burden of parasitemia 182 
during pregnancy in Uganda and Kenya, but there is concern that IPTp with DHA-PQ will 183 
accelerate selection for drug resistance. With simultaneous PK/PD modeling, we used PQ 184 
concentrations and clinical covariates to predict the probability of detecting malaria parasitemia 185 
and the probability of detecting parasites with relevant genotypes associated with drug resistance 186 
in women receiving DHA-PQ or SP as IPTp in Uganda. Higher concentrations of PQ were 187 
needed to reduce the probability of mutant, compared to wild type infections at pfmdr1 86 and 188 
pfcrt 76, but these concentrations were achievable with practical DHA-PQ dosing regimens, 189 
including a novel low dose daily regimen that should minimize toxicity concerns (8, 18). Despite 190 
selection for mutants by DHA-PQ, the overall burden of mutant infections was predicted to be 191 
lower for IPTp with DHA-PQ than with SP. Thus, a low daily dose of DHA-PQ for 192 
chemoprevention during pregnancy is predicted to maximize protective efficacy, with limited 193 
burden of mutant parasites with decreased aminoquinoline sensitivity, and decreased risk, 194 
compared to monthly dosing, of cardiotoxicity (8, 18). 195 
 In our model, we were unable to predict a malaria protective benefit attributable to IPTp 196 
with SP after controlling for covariates. P. falciparum polymorphisms associated with antifolate 197 
resistance were at high prevalence at the study site (16), and there was a high burden of 198 
parasitemia and malarial illness in the SP arm of the study (5). Considering protective efficacy, 199 
monthly DHA-PQ was effective for adult males in Thailand (19), and was superior to SP for 200 
pregnant women in Uganda and Kenya (5, 6), and for children in Uganda (20). But, as with SP, 201 
might regular use of DHA-PQ for IPTp increase the burden of parasites that are no longer 202 
inhibited by the regimen? Importantly, in this setting it does not appear to be the case, as the 203 
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overall reduction in episodes of parasitemia is predicted to lead to a lower burden of infections 204 
with mutant parasites with DHA-PQ as IPTp.  205 
The risk of selecting for P. falciparum with decreased susceptibility to antimalarials will 206 
be dependent on the prevalence of these mutants in the circulating parasite population, as 207 
selection appears to be due primarily to amplification of existing clones, rather than de novo 208 
selection of new mutants (11). Since our trial was conducted, there have been significant 209 
increases in the prevalence of wild type infections at pfmdr1 86 and pfcrt 76 in the region, likely 210 
selected by use of artemether-lumefantrine (AL) to treat malaria in Uganda (14, 21). An 211 
additional wild type polymorphism, pfmdr1 D1246, also increased in prevalence with AL 212 
pressure (14, 21). A haplotype analysis found that mutant pfmdr1 1246Y may be required to 213 
select for pfmdr1 86Y under PQ pressure, further reducing the risk of selecting for pfmdr1 86Y 214 
under DHA-PQ pressure with current circulating parasites (22). In this setting, a recent Ugandan 215 
treatment efficacy study found that, in contrast to results from earlier studies, DHA-PQ did not 216 
select for pfmdr1 and pfcrt mutations in recurrent infections (23).  Considering our modeling 217 
results in this population, it is unlikely that IPTp with DHA-PQ will increase the burden of 218 
mutant parasites with decreased sensitivity to the regimen in Uganda. However, risks of 219 
resistance selection could change over time based on ACT usage or other factors. Longitudinal 220 
surveillance of drug resistance markers and re-evaluation of PK/PD models will remain 221 
important as we consider using DHA-PQ for IPTp.   222 
Our analysis identified important covariates which modified the risk of parasitemia 223 
among women receiving DHA-PQ chemoprevention, including gravidity in the pre-IPTp period, 224 
and trimester and IRS during IPTp. Remarkably, the combination of monthly DHA-PQ and 225 
receipt of IRS eliminated the risk of parasitemia. The benefits of IRS were not as large for the SP 226 
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arm, likely due to persistent parasitemia despite treatment with SP (3). Recent studies from 227 
Uganda found that receipt of IRS is associated with improvements in birth outcomes (24).  Taken 228 
together, available results suggest enormous potential for the joint use of highly effective 229 
intermittent preventive treatment and IRS for the control and potential elimination of malaria. 230 
Our study had some limitations. First, parasitemia was assessed at 28-day intervals. We 231 
could not determine the exact time when an individual became parasitemic, and thus the exact 232 
concentration required to prevent parasitemia. However, monthly PQ concentrations offered a 233 
practical sampling strategy with good predictive power in our models. Second, PK data were not 234 
available to assist in detecting a concentration-effect relationship between SP and prevention of 235 
malaria. We found that, after controlling for covariates which are associated with reduced risk of 236 
malaria infection, a model without an SP effect predicted the data adequately. The absence of a 237 
protective benefit for SP was further supported by a placebo-controlled chemoprevention trial in 238 
Uganda that did not demonstrate a significant protective effect of SP in children (4). Thirdly, 239 
treatment failure due to DHA-PQ resistance and associated genetic markers have not been 240 
identified in Africa and thus could not be used in this analysis. The markers associated with 241 
DHA-PQ resistance in Southeast Asia (pfkelch, plasmepsin2 copy number, and exo-E415G (13, 242 
25, 26)) were assessed for this population and were either not present or, in the case of 243 
plasmepsin2 copy number, only present in a minority of isolates (16). Pfmdr1 86Y and pfcrt 76T 244 
have been consistently associated with PQ exposure in Uganda (17, 27, 28), and have recently 245 
been associated with a modest increase in ex vivo IC50 for PQ (14). As a result, these markers of 246 
antimalarial sensitivity were the most relevant for this population.  247 
By taking a PK/PD modeling approach, we found that higher PQ concentrations are 248 
needed to prevent mutant, compared to wild type malaria infections, but that safe and achievable 249 
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PQ concentrations can provide >99% protection from parasitemia. In addition, a low dose daily 250 
DHA-PQ regimen was predicted to maximally reduce parasitemia. Our findings support the use 251 
of DHA-PQ for chemoprevention and the optimization of DHA-PQ dosing to maximize 252 
protective efficacy while minimizing toxicity and potential selection of drug resistance. Future 253 
clinical trials of DHA-PQ as chemoprevention during pregnancy should consider alternative 254 
dosing strategies, including low dose daily DHA-PQ. 255 
Methods 256 
Study population 257 
Pregnant women were enrolled in the clinical trial that provided samples for our analyses 258 
in Tororo, Uganda from June through October 2014 (5). Eligible women were ≥16 years of age, 259 
HIV-uninfected, and pregnant at 12-20 weeks gestation. Written informed consent was obtained 260 
from all study participants. The study protocol was approved by the Makerere University School 261 
of Biomedical Sciences Research and Ethics Committee, the Uganda National Council for 262 
Science and Technology, and the University of California, San Francisco Committee on Human 263 
Research. The clinical trial registration number is NCT02282293. 264 
Study design and randomization 265 
After enrollment, women randomized to SP (1500 mg sulfadoxine/75 mg pyrimethamine) 266 
every 8 weeks or  DHA-PQ (120 mg DHA/960 mg PQ daily for 3 days) every 8 weeks began 267 
chemoprevention at 20 weeks gestational age, and those randomized to DHA-PQ every 4 weeks 268 
began chemoprevention at either 16 or 20 weeks gestational age. Administration of the first dose 269 
of DHA-PQ was observed in the clinic, and the remaining two doses were taken at home. At 270 
enrollment, study participants received a long-lasting insecticide-treated bed net, underwent a 271 
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physical exam, had height and weight determination, and had blood collected. All women 272 
attended routine visits at 4 week intervals and were asked to return to the clinic for all of their 273 
medical needs. The date of IRS in the household was collected for each subject (24). 274 
Pharmacokinetic sampling 275 
Women randomized to receive DHA-PQ underwent sparse venous (gestational weeks: 276 
20, 28, and 36) and capillary (gestational weeks: 24, 32, and 40) sampling to determine plasma 277 
PQ concentrations (8). Sparse PQ concentrations were determined either 28 days after receiving 278 
the drug in the 4 week DHA-PQ arm or every 28 days and every 56 days after receiving the drug 279 
in the 8 week DHA-PQ arm (8). Venous or capillary specimens were also collected at the time of 280 
any malaria diagnosis. A subset of individuals were enrolled in an intensive PK sub-study. For 281 
this study, as previously reported (29), venous plasma samples were obtained pre-dose, and 0.5, 282 
1, 2, 3, 4, 6, 8, and 24 hours post dose, and capillary plasma samples were collected at 24 hours 283 
and 4, 7, 14 and 21 days post dose. PQ base concentrations were determined using high 284 
performance liquid chromatography tandem mass spectrometry (HPLC-MS) (30). Modification 285 
and partial-validation of the original method for PQ quantitation was performed, to cover a 286 
concentration range of 0.50-1,000 ng/mL, with a coefficient of variation <10% for quality 287 
control samples (30).  288 
P. falciparum detection and genotyping 289 
A blood spot was collected and stored on filter paper at all routine visits and if malaria 290 
was diagnosed at an unscheduled visit. DNA was extracted from dried blood spots using Chelex-291 
100 and tested for the presence of P. falciparum DNA by loop-mediated isothermal amplification 292 
(LAMP) for all microscopy negative samples, as previously described (5, 31). Genotyping for 293 
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pfmdr1 N86Y and pfcrt K76T was conducted using a ligase detection reaction–fluorescent 294 
microsphere assay as previously described (28, 32). Isolates were classified as mutant for either 295 
pure mutant or mixed mutant and wild type genotypes. 296 
PK/PD models 297 
To estimate the concentration effect relationship between PQ PK and probability of 298 
parasitemia, and between PQ PK and the probability of detecting particular alleles at the loci of 299 
interest, simultaneous PK/PD models were developed using nonlinear mixed effects modeling 300 
and LAPLACE methods (33). All available PQ concentration data above the limit of quantitation 301 
were used in the development of a two-compartment PQ PK model, as previously described (8). 302 
The population PQ PK model was then used as part of a simultaneous continuous-categorical 303 
PK/PD model with logit transformation to determine the probability of parasitemia or mutant 304 
genotype. To avoid repeated sampling of persistent circulating parasites, testing for parasitemia 305 
was censored after the first episode of parasitemia identified following each administration of 306 
study drug. Model appropriateness was evaluated by likelihood ratio test, inspection of the 307 
diagnostic plots, and internal model validation techniques, including visual and numerical 308 
predictive checks. 309 
We first developed a simultaneous continuous-categorical PK/PD-parasitemia model to 310 
predict the probability of parasitemia among women who received DHA-PQ. Dose response, 311 
linear, and Emax models were tested for the relationship between PQ concentration and 312 
probability of parasitemia. Gravidity, trimester (defined as <28 weeks for the second trimester 313 
and ≥28 weeks for the third trimester), enrollment BMI, change in BMI compared to enrollment, 314 
dry season (defined as December to February), and receipt of IRS were then tested as covariates 315 
in the model. We then developed a PD model for the probability of parasitemia for women who 316 
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received SP. We estimated that SP had a 28 day effect based on prior modeling studies (34). The 317 
same covariates were tested for SP as for DHA-PQ.  318 
PK/PD-resistance models were developed to estimate the relationship between PQ 319 
concentration and parasite genotype at pfmdr1 N86Y or pfcrt K76T, also using simultaneous 320 
PK/PD modeling with logit transformation. All PQ PK data and available genotype data from 321 
episodes of parasitemia were used to develop models to predict sequences at the pmfdr1 N86Y 322 
and pfcrt K76T alleles when parasitemia was detected. Baseline, dose response, linear, and Emax 323 
relationships between PQ concentration and genotype were tested for those who received DHA-324 
PQ. Since PK data were not available for SP, a PD-resistance model was used to evaluate a study 325 
arm effect of SP chemoprevention on selection for mutant infections compared to the pre-326 
chemoprevention baseline.  327 
The final PK/PD-parasitemia models, with epidemiologic covariates, and PK/PD-328 
resistance models for PQ, were utilized sequentially, and concentrations of PQ needed to prevent 329 
parasitemia with mutant or wild type infections at each locus were defined as the median value 330 
needed to provide 99% protection against parasitemia. One hundred simulations of 1,000 331 
pregnancies were conducted using the final PK/PD models to determine the median number of 332 
parasitemia episodes and mutant parasitemia episodes with 95% confidence intervals for 1,000 333 
pregnancies. Dosing strategies were selected to maximize protective efficacy. Simulated 334 
regimens included monthly dosing (2,880 mg PQ and 360 mg DHA divided into three 335 
consecutive daily oral doses), once weekly dosing (960 mg PQ and 120 mg DHA), and two once 336 
daily dosing options (160 mg PQ with 20 mg DHA and 320 mg PQ with 40 mg DHA). All 337 
statistical analyses were conducted in R (version 3.3.2) and STATA (version 14.2).  338 
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Figure Legends 499 
Figure 1. Trial profile. Study subjects were tested for P. falciparum parasitemia monthly and 500 
when they presented for unscheduled visits due to a febrile illness.  501 
Figure 2. (A) Predicted probability of parasitemia with increasing piperaquine 502 
concentration in the absence of indoor residual spraying of insecticide for women receiving 503 
DHA-PQ stratified by trimester. The solid lines (red, second trimester; blue, third trimester) 504 
show the median probability and shading encompasses probabilities for 95% of the population. 505 
The median probability of parasitemia while receiving SP as IPTp was 39%. Contributions of 506 
mutant and wild type genotypes to overall parasitemia probability during the second 507 
trimester for pfmdr1 86 (B) and pfcrt 76 (C). The black line represents the median probability 508 
of all parasitemia, and shaded areas indicate the proportion of the probability attributed to wild 509 
type (blue) and mutant (red) parasites. Results for the third trimester are shown in Supplemental 510 
Figure 3. 511 
Figure 3. Predicted probability of detecting mutant pfmdr1 86Y (A) or pfcrt 76T (B) 512 
parasites with increasing piperaquine concentrations for women receiving DHA-PQ with 513 
parasitemia. Points are the raw data, showing isolates with mutant (100%) or wild type (0%) 514 
genotypes. (C) Odds of detecting mutant genotypes in the DHA-PQ treatment arms, 515 
compared to the SP arm. The solid line is the median probability or increased odds of detecting 516 
a mutant parasite during an episode of parasitemia and the shading encompasses the probability 517 
or increased odds of detecting a mutant parasite for 95% of the population. 518 
Figure 4. Association between piperaquine concentration and probability of wildtype or 519 
mutant genotype among women in the second trimester receiving DHA-PQ. Probabilities of 520 
detecting pfmdr1 86 (A) or pfcrt 76 (B) genotypes are shown, with closer visualization of the 521 
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curves enclosed in boxes shown for pfmdr1 86 (C) and pfcrt 76 (D). Arrows indicate the 522 
median concentrations (ng/ml) providing 99% protection against parasitemia.  Lines indicate the 523 
median probabilities, and the shading indicates the probability of detecting mutant parasites for 524 
95% of the population. 525 
Figure 5.   (A) Predicted percentage of time above piperaquine concentrations protective 526 
against 99% of parasitemia episodes during pregnancy by DHA-PQ regimen.  Boxes 527 
indicate the interquartile range and error bars represent 95% of the population. (B) Predicted 528 
number of new episodes of parasitemia (gray bars) and episodes of parasitemia with a 529 
mutant infection at pfmdr1 86 (red) and pfcrt 76 (blue) during pregnancy for each 530 
chemoprevention regimen. 531 
 532 
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 534 
 535 
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 538 
 539 
 540 
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Tables 542 
Table 1. Characteristics of study participants. 543 
Characteristic 
SP every 8 
weeks 
N=106 
DP every 8 weeks 
N=94 
DP every 4 weeks  
N=100 
Age in years, mean (SD) 21 (3.6) 22 (4.3) 23 (4.0) 
Gravidity (%)    
 1 42 (40%) 33 (35%) 36 (36%) 
 2 32 (30%) 28 (30%) 28 (28%) 
 ≥3 32 (30%) 33 (35%) 36 (36%) 
Gestational age at first study drug treatment (%) 
 16 weeks - - 68 
 20 weeks 106 94 32 
Number of PQ concentration observations    
 Venous - 300 352 
 Capillary - 278 280 
Visits after participant received indoor 
residual spraying of insecticide 
101 101 153 
First episodes of parasitemia after each 
administration of study druga 
140 37 30 
Genotypes    
 pfmdr1 N86Y genotype available (%) 117 (84%) 37 (100%) 28 (93%) 
 pfmdr1 86Y (%) 32 (27%) 18 (49%) 24 (86%) 
 pfcrt K76T genotype available (%) 122 (87%) 37 (100%) 28 (93%) 
 pfcrt 76T (%) 92 (82%) 31 (84%) 26 (93%) 
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a To avoid consideration of effects of AL or repeat observations of the same parasites, parasitemia 544 
detected after treatment with AL and before subsequent receipt of DHA-PQ or parasites detected 545 
repeatedly without interval receipt of DHA-PQ were excluded. 546 
Table 2. Pharmacokinetic/pharmacodynamic model parameters. 547 
Model/Parameter 
Parameter 
Estimate RSE (%) 
Between Subject 
Variability (CV%) RSE (%) 
Sulfadoxine-pyrimethamine pharmacodynamic model 
 Baseline logit -.441 39% 115% 14% 
 Primigravid baseline 
logita 
.511 
78% - - 
 Indoor residual spraying -.72 60% - - 
 Dry season -1.13 28% - - 
Dihydroartemisinin-piperaquine pharmacokinetic/pharmacodynamic model for parasitemia 
 Baseline logit -.508 72% 73% 17% 
 Primigravid baseline 
logita 
.582 
64% - - 
 Slope of concentration 
 dependent effect (mL/ng) 
-.204 16% - - 
 Indoor residual spraying -10 FIXED - - - 
 Third trimester -1.45 45% - - 
Dihydroartemisinin-piperaquine pharmacokinetic/pharmacodynamic model for pfmdr1 N86Y 
 Baseline logit -1.16 11% 3.8% 53% 
 Slope of concentration  
 dependent effect 
.317 21% - - 
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Dihydroartemisinin-piperaquine pharmacokinetic/pharmacodynamic model for pfcrt K76T 
 Baseline logit 1.06 11% 2.2% 22% 
 Slope of concentration  
 dependent effect 
.218 22% - - 
a Baseline logit used for all gravidities after start of IPTp as gravidity was not a significant predictor of 548 
parasitemia after the start of chemoprevention.549 
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Table 3. Predicted number of mutant infections after starting chemoprevention per 1,000 pregnancies by dosing regimen
a
. 550 
   pfmdr1 86Y pfcrt 76T 
Piperaquine dose 
Number of 
infections per 
1,000 pregnancies 
(95% CI) 
Mutant 
Infections  
(95% CI) 
Ratio of 
mutant 
infections 
DP/SP p-value 
Mutant infections 
(95% CI) 
Ratio of 
mutant 
infections 
DP/SP p-value 
      0 mg (SP) 2066 (1988-2162) 607 (570-650) - - 1564 (1495-1564) - - 
      2,880 mg monthly 317 (280-358)  198 (165-232) .32 <.001 283 (248-315) .18 <.001 
      960 mg weekly 105 (85-122) 87 (71.0-104) .14 <.001 99 (80.4-115) .06 <.001 
      160 mg daily 8.0 (4.0-14.0) 8.0 (3.5-13.5) .01 <.001 8.0 (4.0-14.0) .005 <.001 
      320 mg daily 1.0 (1.0-2.1) 1.0 (.96-2.1) .002 <.001 1 (1.0-2.1) .001 <.001 
a Estimated based on monthly surveillance for parasitemia in the absence of indoor residual spraying of pesticide or seasonal variation in 551 
transmission 552 
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